News

WE LIKE TO KEEP YOU UPDATED

NEWS

FINANCIAL TIMES GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY CONFERENCE

General / 22. November 2018

FINANCIAL TIMES GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY CONFERENCE

05 – 06 November 2018 | London
Keynote Interview:
Medicinal Cannabis: Perspectives on a Growing Market, Evolving Regulations and a Nascent Supply Chain
Andrew Badrot, Founder and CEO, C2 PHARMA

Read more
C<sup>2</sup> PHARMA and ANKLAM EXTRAKT® announce R&D collaboration to develop cannabidiol-based compounds

Press Release / 5. October 2018

C2 PHARMA and ANKLAM EXTRAKT® announce R&D collaboration to develop cannabidiol-based compounds

Luxembourg and Anklam, October 5, 2018 – C2 PHARMA (Hall 6, Booth 6F40) and ANKLAM EXTRAKT (Hall 5, Booth 5G60) are announcing at CPhI 2018 in Madrid their R&D collaboration to develop GMP-compliant manufacture of cannabidiol CBD-based compounds. The collaboration between two leading companies in their respective fields covers various botanicals extracted from cannabis for pharmaceutical use.

Read more
C<sup>2</sup> PHARMA successfully completes validation campaigns for digoxin and digoxin micron

Press Release / 4. October 2018

C2 PHARMA successfully completes validation campaigns for digoxin and digoxin micron

Luxembourg, October 4, 2018 – C2 PHARMA (Hall 6, Booth 6F40) has successfully validated its manufacturing process for two APIs: digoxin and digoxin micron. Digoxin is produced at a dedicated manufacturing facility at CMO Laurus Labs, India.

Read more
C<sup>2</sup> PHARMA AND THERACULE ANNOUNCE STRATEGIC PARTNERSHIP

Press Release / 4. October 2018

C2 PHARMA AND THERACULE ANNOUNCE STRATEGIC PARTNERSHIP

Luxembourg and Oslo, October 4, 2018 – C2 PHARMA (Hall 6, Booth 6F40) and Theracule AS are entering into a strategic partnership focused on supporting Theracule’s new drug development programs aimed at rare neurodevelopmental disorders.

Read more
C<sup>2</sup> PHARMA brings reliable cannabidiol (cbd) api source to pharma companies and expands its r&d product pipeline

General / 2. October 2018

C2 PHARMA brings reliable cannabidiol (cbd) api source to pharma companies and expands its r&d product pipeline

Luxembourg, October 2, 2018 – C2 PHARMA (Hall 6, Booth 6F40) has announced a major expansion of its R&D program to grow its API portfolio at CPhI 2018 in Madrid. The R&D program covers synthetic APIs as well as naturally extracted APIs and botanicals for pharmaceutical use.

Read more
C<sup>2</sup> PHARMA buys out joint venture partner

Press Release / 22. June 2018

C2 PHARMA buys out joint venture partner

Luxembourg & São Paulo – 22 June, 2018 – C2 PHARMA has acquired the remaining 50 % of the shares in its joint venture from PAMA Holding, the investment vehicle of the Centroflora Group in Luxembourg. CEO Andrew Badrot is now the sole shareholder of C2 PHARMA.

Read more
CPhI 2017: C<sup>2</sup> PHARMA acquires R&D synthesis services company and establishes cold-chain logistics spin-off

General / 16. October 2017

CPhI 2017: C2 PHARMA acquires R&D synthesis services company and establishes cold-chain logistics spin-off

Luxembourg, October 16, 2017 – C2 PHARMA (Hall 11, Level 0, #B40), the company formerly known as Centroflora CMS, has announced the acquisition of German R&D synthesis services company ASM Research Chemicals in the run-up to the CPhI Worldwide exhibition in Frankfurt am Main, Germany on 24- 26 October 2017.

Read more
Centroflora CMS changes its name to C<sup>2</sup> PHARMA

General / 4. October 2017

Centroflora CMS changes its name to C2 PHARMA

The anticipated formal registration of the company’s name (C-squared Pharma S.à r.l) with the Luxembourg authorities is expected to be concluded in December 2017, followed by the regulatory update to the CEP and US-DMF filings for Atropine Sulfate and Homatropine Methylbromide at the competent authorities.

Read more
CPhI 2017: Centroflora CMS gains CEP approvals and invests in Digoxin manufacturing facility in India

General / 2. October 2017

CPhI 2017: Centroflora CMS gains CEP approvals and invests in Digoxin manufacturing facility in India

CEP approval for atropine sulfate; availability of US-DMFs for reference for both atropine sulfate and homatropine methylbromide.

Read more
CPhI 2017: Centroflora CMS nominated for the 2017 CPhI Pharma Award for Corporate Social Responsibility

General / 20. September 2017

CPhI 2017: Centroflora CMS nominated for the 2017 CPhI Pharma Award for Corporate Social Responsibility

Centroflora CMS has again been nominated for the CPhI Award in the category “Excellence in Pharma: Corporate Social Responsibility” for the project “Partnership for a Better World”. This is the second year in succession that the company has been in the running for the Award.

Read more
Centroflora CMS at CPhI 2017 in Frankfurt – booth 11.0.B40

General / 5. September 2017

Centroflora CMS at CPhI 2017 in Frankfurt – booth 11.0.B40

Please join us at our booth 11.0.B40 under the Brazilian Pavillion at CPhI Frankfurt on October 24 and 26, 2017.

Read more
Centroflora CMS is Selected as Finalist for the CPhI Pharma Awards 2016

General / 19. September 2016

Centroflora CMS is Selected as Finalist for the CPhI Pharma Awards 2016

Centroflora CMS is selected as a finalist for the CPhI Pharma Awards 2016 in the category Excellence in Pharma: Corporate Social Responsibility.

Read more
Centroflora CMS at CPhI 2016 in Barcelona – booth 3H10

General / 9. September 2016

Centroflora CMS at CPhI 2016 in Barcelona – booth 3H10

Please join us at our booth 3H10 under the Brazilian Pavillion at CPhI Barcelona on October 4 and 6, 2016.

Read more
Centroflora CMS is the winner of the 2015 CPhI Pharma Award for Excellence in Partnering & Outsourcing

General / 27. October 2015

Centroflora CMS is the winner of the 2015 CPhI Pharma Award for Excellence in Partnering & Outsourcing

We are pleased to announce that Centroflora CMS won the prestigious 2015 CPhI Pharma Awards for Excellence in Partnering & Outsourcing. Awarded by CPhI Worldwide (UBM EMEA), 16 finalists were invited to present their case during the first day of CPhI Worldwide in Madrid on October 13, 2015.

Read more
Centroflora CMS Expands its Product and Service Offering

General / 4. October 2015

Centroflora CMS Expands its Product and Service Offering

New service offering includes R&D leveraging a unique bioprospecting platform from the Brazilian biomes as well as contract manufacturing (CMO) services for both API and botanical extracts in Brazil.

Read more
Centroflora CMS is Selected as Finalist for the CPhI Pharma Awards 2015

General / 21. September 2015

Centroflora CMS is Selected as Finalist for the CPhI Pharma Awards 2015

Centroflora CMS is selected as a finalist for the CPhI Pharma Awards 2015.

Read more
Centroflora CMS at CPhI 2015 in Madrid

General / 1. September 2015

Centroflora CMS at CPhI 2015 in Madrid

Please join us at our booth 8D20 under the Brazilian Pavillion at CPhI Madrid between October 13 and 15, 2015.

Read more
Centroflora Group is Awarded 1st National Biodiversity Award

General / 22. May 2015

Centroflora Group is Awarded 1st National Biodiversity Award

Centroflora Group receives the Brazilian Ministry of Environment 1st National Biodiversity Award in recognition of the Jaborandi Valorization Project.

Read more
Firms Team Up To Sustain Natural Pilocarpine

General / 16. March 2015

Firms Team Up To Sustain Natural Pilocarpine

C&EN’s Rick Mullin writes about Centroflora CMS and Centroflora’s Partnership for a Better World.

Read more
Centroflora CMS Enters an Exclusive Agreement to Distribute N-Butyl Scopolamine Globally

General / 1. January 2015

Centroflora CMS Enters an Exclusive Agreement to Distribute N-Butyl Scopolamine Globally

Boehringer Ingelheim awards Centroflora CMS the exclusive distribution rights for N-Butyl Scopolamine (SNBB) globally. This decision demonstrates and fully aligns with Boehringer Ingelheim long-term commitment to remain a key manufacturer of SNBB while Centroflora CMS is to assume market supply responsibilities as of January 1, 2015.

Read more